IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 251-275 out of 1263.

<< < 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 > >>

Public Release: 26-Feb-2015
Cell
Novel precision medicine tool could help personalize cancer treatments
A new laboratory test accurately predicted which of many drug treatments would most effectively kill cancer cells in the laboratory and in the clinic. If validated in ongoing clinical trials, the test could be ready to inform patient care in about two years.
National Institutes of Health

Contact: Teresa M Herbert
teresa_herbert@dfci.harvard.edu
617-632-5653
Dana-Farber Cancer Institute

Public Release: 26-Feb-2015
Journal of the National Cancer Institute
Statin use associated with reduced risk of liver cancer among those in the UK
In a nested-case control study of individuals living in the UK, a part of the world with a relatively low incidence of liver cancer, statin use is associated with a decreased risk of liver cancer, according to a new study published Feb. 26 in the JNCI: Journal of the National Cancer Institute.

Contact: Zachary Rathner
Zachary.Rathner@oup.com
919-677-2697
Oxford University Press USA

Public Release: 25-Feb-2015
Oncotarget
Graphene shows potential as novel anti-cancer therapeutic strategy
University of Manchester scientists have used graphene to target and neutralize cancer stem cells while not harming other cells.

Contact: Jamie Brown
Jamie.brown@manchester.ac.uk
44-016-127-58383
University of Manchester

Public Release: 25-Feb-2015
Oncotarget
Novel anti-cancer DNA vaccine may fight aging, chronic inflammation and osteoporosis
The CureLab consortium has discovered a DNA vaccine, which systemically alleviates chronic inflammation in the body. Preventive and therapeutic effects of the new vaccine were demonstrated in osteoporosis mouse models. A paper reporting these results is just published in the journal Gerotarget. Alleviating chronic inflammation may constitute an alternative application for the CureLab vaccine, which recently demonstrated great potency as a veterinary anticancer agent and currently is in phase I of anticancer clinical trials.

Contact: Nathan Fridlyand
Nathan@curelab.com
609-841-1201
Cure Lab, Inc.

Public Release: 25-Feb-2015
Nature
How the landscape of the pancreatic cancer genome is coming into view
Scientists from Australia and the UK have done the most in-depth analysis yet of 100 pancreatic cancer genomes and highlighted four subtypes that may help guide future patient treatment. The study is published in Nature today.
National Health and Medical Research Council of Australia, Cancer Council NSW, Cancer Institute NSW, Queensland Government, Institute of Molecular Bioscience at the University of Queensland, Avner Nahmani Pancreatic Cancer Foundation

Contact: Alison Heather
a.heather@garvan.org.au
61-292-958-128
Garvan Institute of Medical Research

Public Release: 25-Feb-2015
PLOS ONE
Culture clash: How stem cells are grown affects their genetic stability
Writing in the Feb. 25 online issue of the journal PLOS ONE, researchers at University of California, San Diego School of Medicine, with collaborators from The Scripps Research Institute, have definitively shown for the first time that the culture conditions in which stem cells are grown and mass-produced can affect their genetic stability.
California Institute for Regenerative Medicine, National Institutes of Health, UC San Diego Department of Reproductive Medicine, the Hartwell Foundation, Millipore Foundation, Esther O'Keefe Foundation, Marie Mayer Foundation, Autism Speaks

Contact: Scott LaFee
slafee@ucsd.edu
619-543-6163
University of California - San Diego

Public Release: 25-Feb-2015
Nature Reviews Clinical Oncology
What does the future hold for treating patients with locally advanced breast cancer?
Treating patients with locally advanced inoperable breast cancer is an extremely difficult task. The overwhelming majority of patients treated for this disease suffer relapse and, despite the best multimodal treatment, do not survive. There is a medical need to examine current and potential treatments, and EORTC researchers have recently published an article in Nature Reviews Clinical Oncology concerning this topic.

Contact: John Bean
john.bean@eortc.be
European Organisation for Research and Treatment of Cancer

Public Release: 25-Feb-2015
Addiction
Shopping vouchers could help 1 in 5 pregnant women quit smoking
Financial incentives could help one in five women quit smoking during pregnancy, according to new research published today in the journal Addiction. The study, led by researchers at the University of Cambridge and King's College London, found that only a small number of women 'gamed' the system to receive the incentives whilst continuing to smoke.
NHS Derbyshire County Primary Care Trust, Derbyshire County Council, Wellcome Trust

Contact: Craig Brierley
craig.brierley@admin.cam.ac.uk
44-012-237-66205
University of Cambridge

Public Release: 25-Feb-2015
Pain
One in 3 women could potentially be spared chronic pain after breast cancer surgery
One in every three women undergoing a mastectomy could potentially be spared chronic post-operative pain if anesthesiologists used a regional anesthetic technique in combination with standard care, according to a new study.
Funders listed in release

Contact: Geoff Koehler
koehlerg@smh.ca
416-864-6060 x6537
St. Michael's Hospital

Public Release: 25-Feb-2015
Physics in Medicine and Biology
Cherenkov Effect improves radiation therapy for patients with cancer
The characteristic blue glow from a nuclear reactor is present in radiation therapy, too. Investigators from Dartmouth's Norris Cotton Cancer Center published in Physics in Medicine and Biology how the complex parts of the blue light known as the Cherenkov Effect can be measured and used in dosimetry to make therapies safer and more effective.
National Institutes of Health

Contact: Kirk Cassels
Kirk.A.Cassels@Hitchcock.org
603-653-6177
The Geisel School of Medicine at Dartmouth

Public Release: 25-Feb-2015
Open Biology
Molecular mouse-trap technique sheds light on key cell processes
Scientists have shed new light on the fundamental biological process of cell division, thanks to an emerging analytical method.
Wellcome Trust

Contact: Catriona Kelly
Catriona.Kelly@ed.ac.uk
44-131-651-4401
University of Edinburgh

Public Release: 25-Feb-2015
Nature
Researchers find link between inflammation, tissue regeneration and wound repair response
Writing in the Feb. 25 online issue of Nature, an international team of scientists, headed by researchers at the University of California, San Diego School of Medicine, report finding new links between inflammation and regeneration: signaling pathways that are activated by a receptor protein called gp130.
Japan Society for the Promotion of Science, Uehara Memorial Foundation, Mochida Memorial Foundation for Medical and Pharmaceutical Research, Kanae Foundation for the Promotion of Medical Science

Contact: Scott LaFee
slafee@ucsd.edu
619-543-6163
University of California - San Diego

Public Release: 25-Feb-2015
Chemistry - A European Journal
New compound may lead to development of cheaper anti-cancer drugs
A new compound developed at the University of Toronto Scarborough could play an important role in developing cheaper anti-cancer drugs.
Natural Sciences and Engineering Research Council of Canada

Contact: Don Campbell
dcampbell@utsc.utoronto.ca
416-208-2938
University of Toronto

Public Release: 25-Feb-2015
Veterinary and Comparative Oncology
Study reveals possible biological trigger for canine bone cancer
Researchers at the University of Wisconsin-Madison School of Veterinary Medicine have identified the biological mechanism that may give some cancer cells the ability to form tumors in dogs. The recent study uncovered an association between the increased expression of a particular gene in tumor cells and more aggressive behavior in a form of canine bone cancer. It may also have implications for human cancers by detailing a new pathway for tumor formation.

Contact: Timothy Stein
tjstein@wisc.edu
608-890-3268
University of Wisconsin-Madison

Public Release: 25-Feb-2015
Pediatric Blood and Cancer
Quick antibiotics reduce PICU needs and mortality of pediatric cancer patients
A University of Colorado Cancer Center study published in the journal Pediatric Blood & Cancer shows that pediatric cancer patients who receive antibiotics within 60 minutes of reporting fever and showing neutropenia (low neutrophil count), go on to have decreased intensive care needs and lower mortality compared with patients who receive antibiotics outside the 60-minute window.

Contact: Garth Sundem
garth.sundem@ucdenver.edu
University of Colorado Denver

Public Release: 25-Feb-2015
American Journal of Public Health
Navigators help patients overcome health-care inequities
A new study shows that guidance from trained navigators can help patients overcome health-care inequities. Community navigators worked with uninsured Spanish-speaking women to obtain timely follow-up care after an abnormal breast or cervical cancer screening result. Postponed diagnosis after an abnormal test can lead to less effective treatment and lower chances of survival.
National Institutes of Health

Contact: Marla Paul
marla-paul@northwestern.edu
Northwestern University

Public Release: 24-Feb-2015
Journal of Immigrant and Minority Health
Filipino newcomers to Canada diagnosed with breast cancer at a younger age
Filipinos who move to Canada are diagnosed with breast cancer at a younger age than women from other parts of East Asia or Caucasians, new research has found.

Contact: Leslie Shepherd
shepherdl@smh.ca
416-864-6094
St. Michael's Hospital

Public Release: 24-Feb-2015
PLOS Medicine
'Patchwork' ovarian cancer more deadly
The most common type of ovarian cancer is more deadly if it consists of a patchwork of different groups of cells, according to a Cancer Research UK study published today in PLOS Medicine.

Contact: Emily Head
emily.head@cancer.org.uk
44-203-469-6189
Cancer Research UK

Public Release: 24-Feb-2015
Nature Reviews Cancer
Scientists find cancer weak spots for new targeted drugs
Scientists have identified weak spots in cancer cells that could be targeted and attacked by new precision drugs.
Cancer Research UK

Contact: James Hakner
press@sussex.ac.uk
44-127-367-8888
University of Sussex

Public Release: 24-Feb-2015
JAMA
Inherited gene variation leaves young leukemia patients at risk for peripheral neuropathy
Researchers have identified the first genetic variation that is associated with increased risk and severity of peripheral neuropathy following treatment with a widely used anti-cancer drug. Investigators also found evidence of how it may be possible to protect young leukemia patients without jeopardizing cures. St. Jude Children's Research Hospital scientists led the study, which appears today in the Journal of the American Medical Association.
National Institutes of Health, American Lebanese Syrian Associated Charities

Contact: Carrie Strehlau
carrie.strehlau@stjude.org
901-595-2295
St. Jude Children's Research Hospital

Public Release: 24-Feb-2015
Clinical Cancer Research
TGen study: Destroying tumor material that 'cloaks' cancer cells could benefit patients
Like a stealth jet cloaks itself from radar, cancer cells cloak themselves within tumors by hiding behind a dense layer of cellular material known as stroma. According to a new study by the Translational Genomics Research Institute, drugs that target and strip away the stroma would pave the way for drugs to reach the cancerous cells within the tumor, which could have a beneficial effect on the survival of pancreatic cancer patients.
NIH/National Cancer Institute, Stand Up To Cancer, Katz Family Foundation, National Foundation for Cancer Research

Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute

Public Release: 24-Feb-2015
ACS Nano
Cutting-edge technology optimizes cancer therapy with nanomedicine drug combinations
Designing optimized combination therapies for cancer is remarkably difficult due to the infinite possible drug dose ratios and variable patient-specific response to treatment. In a landmark advance for personalized medicine, University of California Los Angeles bioengineers have developed a novel technology that, for the first time, overcomes these challenges. By assessing phenotype, or physical biological traits as they respond to chemotherapy to drive a powerful analytics platform, the most effective and safe drug combinations possible can be systematically designed.

Contact: Brianna Aldrich
baldrich@dentistry.ucla.edu
310-206-0835
University of California - Los Angeles

Public Release: 24-Feb-2015
Urology Practice
New health care delivery model for prostate cancer care results in better patient outcomes
A comprehensive, population-based regional health care management program for men with prostate cancer who are members of Kaiser Permanente Southern California has led to improved outcomes, according to a Kaiser Permanente study published today in the journal Urology Practice.

Contact: Vincent Staupe
vstaupe@golin.com
415-318-4386
Kaiser Permanente

Public Release: 24-Feb-2015
Molecular Cancer Therapeutics
Even low-androgen triple-negative breast cancer responds to anti-androgen therapy
Clinical trials are underway of anti-androgen drugs against high-androgen triple-negative breast cancers, and new work from the University of Colorado Cancer Center shows the threshold for benefit from anti-androgen therapies may be much lower than previously thought: even breast cancers with few androgen receptors benefit from anti-androgen therapy.
US Department of Defense

Contact: Garth Sundem
garth.sundem@ucdenver.edu
University of Colorado Denver

Public Release: 24-Feb-2015
ACS Nano
Together, nanotechnology and genetic interference may tackle 'untreatable' brain tumors
There are no effective available treatments for sufferers of Glioblastoma multiforme, the most aggressive and devastating form of brain tumor. Now a new Tel Aviv University study may offer hope to the tens of thousands diagnosed with gliomas every year, using a nanomedical treatment first engineered to tackle ovarian cancer tumors.

Contact: George Hunka
ghunka@aftau.org
212-742-9070
American Friends of Tel Aviv University

Showing releases 251-275 out of 1263.

<< < 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 > >>

  Search News Releases

     

 

EurekAlert!